Abstract
Objective: Vitamin D deficiency was associated with CTD-ILD and reduced lung function. We sought to confirm that lower Vitamin D level would be related to shorter survival times.Results: The CTD-ILD patients had lower Vitamin D level(P<0.05). Among patients with CTD-ILD who have improved lung function after treatment, elevation of Vitamin D level was positively associated with ΔFVC (%), ΔFEV1(%) and ΔDLCO-SB (%). The median survival time of patients with high serum 25(OH)D level was significantly longer than the patients with low 25(OH)D level group (16.5 months vs14.0 months, P=0.007). The Vitamin D was identified as an independent prognostic factor with a hazard ratio of 0.869 (95% CI 0.772-0.977, P =0.019).Conclusions: Vitamin D level was lower in patients with CTD-ILD and associated with poor prognosis. Continuous levels of Vitamin D may be an important serum biomarker of prognosis.Methods: 85 CTD-ILD patients, 71 Idiopathic pulmonary fibrosis (IPF) patients and 78 healthy control patients were included in the study. In the subgroup analysis, the CTD-ILD patients were divided into anti-MDA5 antibody-positive group and anti-MDA5 antibody-negative group according to the serum autoantibodies results. The survival analysis evaluated effect of Vitamin D level on disease prognosis.
Highlights
Interstitial lung disease (ILD) is strongly associated with connective tissue disease (CTD) including polymyositis/dermatomyositis (PM/DM), systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjögren’s syndrome, and so on [1]
The serum 25(OH)D levels were obviously lower in patients with CTD-ILD compared with the Idiopathic pulmonary fibrosis (IPF) group (P
The serum 25(OH)D levels were obviously lower in patients with CTD-ILD compared with the IPF group (P < 0.05) and the control group (P < 0.05). (B) The CTD-ILD groups were divided into two subgroups: anti-MDA5 antibody-positive and anti-MDA5 antibody-negative groups
Summary
Interstitial lung disease (ILD) is strongly associated with connective tissue disease (CTD) including polymyositis/dermatomyositis (PM/DM), systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjögren’s syndrome, and so on [1]. It reported that the median survival time for CTD-ILD patients was roughly 6.5 years, and the mortality rate due to CTD attributable to ILD was approximately 123.6 per 1000 person years [2, 3], but the progression and prognosis of CTD-ILD varies widely between individuals [4]. There was no disease-specific biomarker in CTD-ILD that can predict disease progression and prognosis
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
